Issues

ABOUT THE COVER
T cell-dependent bispecific antibodies (TDBs) form immunological synapses between cancer cells and T cells. Cancer cell killing occurs when TDB simultaneously binds a cancer cell surface antigen and T cell receptors, such as CD3. TDBs can be tracked in vivo using radioimmunoconjugates that elucidate distinct metabolic fates. Upon target binding, a fraction of the antibody-receptor complex is internalized and directed for lysosomal degradation. Catabolites of ¹²⁵I-labeled TDBs freely diffuse across the cellular membrane, likely followed by entry to systemic circulation and renal clearance. ¹²⁵I-labeled TDBs indicate the proportion of TDBs available to form cytolytic synapses. Illustration credit: Allison Bruce, Genentech.